Company Overview and News
Late Friday last week, little known Pinehill Pacific Bhd (formerly known as Multi Vest Resources Bhd, which by the way was formerly known as Best World Land Bhd) surprised the market with the announcement that it was parting with nearly 9,000 acres of landbank and related plantation assets held via three subsidiary companies to United Plantations Bhd (UP) for a whopping sum of RM413.6mil.
2038 5138 1996 UPBMF 4383 7501 1902 2089 5112
Plantation sector Maintain neutral: Malaysia’s crude palm oil (CPO) production increased for a second straight month in August, rising by 7.9% month-on-month (m-o-m) to 1.62 million tonnes. The fresh fruit bunch (FFB) yield also improved across Peninsular Malaysia, Sabah and Sarawak, rising by 8.7%, 3.2% and 12.6% year-on-year (y-o-y) respectively to 1.38 tonnes/ha, 1.28 tonnes/ha and 1.52 tonnes/ha.
KLKBY 2445 5138 2216 4383 2291 4243 5012
KUALA LUMPUR: Builder and property developer IJM Corp Bhd expects a lower order book replenishment in the current financial year ending March 31, 2019 (FY19) as it already secured some of the jobs in FY18.
KLKBY 2445 5138 2216
KUALA LUMPUR (Aug 28): Hap Seng Plantations Holdings Bhd's net profit for the second quarter ended June 30, 2018 (2QFY18) slumped 85% to RM3.94 million from RM26.31 million a year ago, on lower revenue as a result of lower average selling prices and sales volume of crude palm oil (CPO) and palm kernel (PK).
KUALA LUMPUR (Aug 28): IJM Corp Bhd today described as “mere speculation” news reports that the group has received offers to acquire its 56% stake in IJM Plantations Bhd.
KLKBY 2445 5138 2216
KUALA LUMPUR (Aug 7): IJM Plantations Bhd gained as much as 22 sen or 9.78% to a six-month high of RM2.47 in early trade today after a news report cited the company as a takeover target.
High demand: Among the suitors eyeing IJM Plantations, which has 61,000ha of planted area in Sabah, Kalimantan and Sumatra, are plantation groups such as IOI and Hap Seng Plantations.
5138 1996 2216 5254
In the hey days of the market in the 1990s, public viewing galleries will cheer every time when they see Kretam Holdings Bhd ’s (Kretam) share price move along with other market darlings of the yesteryear. They would say in the Malay language, “Ketam mari, Ketam mari”, as in the stock is having an upward run and it’s time to “jump in.”
Hap Seng Plantations Holdings Bhd (June 19, RM2.21) Upgrade to market perform with a higher target price (TP) of RM2.15: Hap Seng Plantations Holdings Bhd announced that it had terminated its share sale agreement to acquire 55% of Kretam Holdings Bhd from Datuk Lim Nyuk Sang @ Freddie Lim and Santaprise Sdn Bhd after finalising its due diligence process and finding the results “unsatisfactory and unacceptable”.
KUALA LUMPUR: Kretam Holdings Bhd’s share price yesterday sank to its lowest since September 2015 with some half a billion ringgit worth of market capitalisation wiped out in a day, after Hap Seng Plantations Holdings Bhd called off a plan to take up a controlling 55% stake in the company.
Hap Seng Consolidated Bhd (+ve) TRADING of the shares in Hap Seng Consolidated Bhd (fundamental: 1.3/3, valuation: 1.3/3) triggered our momentum algorithm last Thursday for the first time this year. The group saw 937,700 shares traded.
5138 1996 3034
KUALA LUMPUR (June 18): Kretam Holdings Bhd's stock price nosedived in early trade today to its lowest since September 2015, after its plans to sell a 55% stake to Hap Seng Plantations Holdings Bhd had been called off.
5138 1996 BSMAF 1818
KUALA LUMPUR: Kretam Holdings Bhd ’s shares fell over 35% in early trade, on news that Hap Seng Plantations Holdings Bhd had dropped its RM1.18bil takeover bid.
5138 1996 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...